In Vitro Evaluation of Combination Therapy with Doxorubicin and Quercetin for Uveal Melanoma
Current Issues in Molecular Biology · 18.06.2026 · 48 (6) · 636
DOI: 10.3390/cimb48060636 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 18.06.2026. Verfasst von Petra Fodor und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Culture and Innovation, Ministry of Culture and Innovation of Hungary.
Abstract (Originalsprache)
Background
Uveal melanoma is the most common intraocular malignancy in adults with a poor prognosis. Although local therapies are effective, treatment options for advanced disease remain limited. Combination strategies using chemotherapeutic agents and natural compounds, such as quercetin, are in focus for their potential to enhance antitumor efficiency and overcome resistance.
Methods
The effects of doxorubicin, quercetin, and their combination were investigated in uveal melanoma cell lines. Cell viability was determined by an MTT assay, and apoptosis and cell cycle distribution by flow cytometry. Invasion assays were performed to evaluate metastatic potential, while modifications in signaling pathways were analyzed by Western blotting and qPCR.
Results
Both doxorubicin and quercetin significantly reduced cell viability and induced apoptotic and necrotic cell death. The combination treatment demonstrated additional inhibitory effects in both cell lines, shown by increased SubG1 populations, reduced invasive capacity, and modulation of signaling pathways. Cell cycle analysis indicated treatment-induced growth inhibition. Notably, pathway modifications varied between cell lines, suggesting heterogeneous responses.
Conclusions
Quercetin may potentiate certain antitumor effects of doxorubicin in uveal melanoma, particularly by reducing post-treatment invasiveness and modulating certain PI3K/AKT pathway-related proteins. These results support the possibility of quercetin-based combination therapies, although further molecular and in vivo studies are required.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary.
- Doctoral School of Pharmaceutical Sciences, University of Debrecen, 4032 Debrecen, Hungary.
- Department of Molecular and Nanopharmaceutics, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary.
ORCID-Profile: Barbara Zsebik, Ferenc Fenyvesi
Förderung
- Ministry of Culture and Innovation
- Ministry of Culture and Innovation of Hungary
Zitieren
APA
Fodor, P., Zsebik, B., Fenyvesi, F., Szabó, Z., Vass, A., & Halmos, G. (2026). In Vitro Evaluation of Combination Therapy with Doxorubicin and Quercetin for Uveal Melanoma. Current Issues in Molecular Biology, 48(6), 636. https://doi.org/10.3390/cimb48060636
Vancouver
Fodor P, Zsebik B, Fenyvesi F, Szabó Z, Vass A, Halmos G. In Vitro Evaluation of Combination Therapy with Doxorubicin and Quercetin for Uveal Melanoma. Current Issues in Molecular Biology. 2026;48(6):636. doi:10.3390/cimb48060636
BibTeX
@article{Fodor2026,
author = {Fodor, Petra and Zsebik, Barbara and Fenyvesi, Ferenc and Szabó, Zsuzsanna and Vass, Anna and Halmos, Gábor},
title = {In Vitro Evaluation of Combination Therapy with Doxorubicin and Quercetin for Uveal Melanoma},
journal = {Current Issues in Molecular Biology},
year = {2026},
volume = {48},
number = {6},
pages = {636},
doi = {10.3390/cimb48060636}
}
EUVIMED